Orchid Pharma share news, announcements and annual reports
NSE: ORCHPHARMABSE: 524372Pharmaceuticals & BiotechnologySmall Cap
Orchid Pharma Limited · Formerly Orchid Chemicals & Pharmaceuticals · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 1993 on BSE, Jul 2010 on NSE
Last close ₹836.45down ₹56.95 (6.37%)BSE ₹833.05
Share price at the NSE close on 30 Oct 2026. Previous close ₹893.40.
30 Oct: open ₹893.45, high ₹893.45, low ₹830.00
52-week range of traded prices to 30 Oct 2026
₹480.00Low, 30 Mar 2026₹1,143.50High, 22 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹5,009 Cr919th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 0.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.19
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 88,12456.8% delivered
Orchid Pharma share news and announcements
856 announcements, routine notices left out, newest first. Page 17 of 18.
May 2008
29 May · Dividend
Board of Directors of the Company at its meeting held on May 29, 2008 has recommended a dividend of 30% (Rs.3/- per share) on the equity share of Rs.10/- each.29 May · Results
Standalone Results for the quarter ended on 31-MAR-2008 as follows: Net Sales of Rs. 37919.36 lacs for quarter ending on 31-MAR-2008 against Rs. 24800.11 lacs for the quarter ending on 31-MAR-2007. Net Profit / (Loss) of Rs. 1584.81 lacs for the quarter ending on 31-MAR-2008 against Rs. 2426.67 lacs for the quarter ending on 31-MAR-2007.29 May · Results
Standalone Results for the year ended on 31-MAR-2008 as follows: Net Sales of Rs. 123891.62 lacs for year ending on 31-MAR-2008 against Rs. 93417.55 lacs for the year ending on 31-MAR-2007. Net Profit / (Loss) of Rs. 18453.61 lacs for the year ending on 31-MAR-2008 against Rs. 9663.18 lacs for the year ending on 31-MAR-2007.29 May · Results
Consolidated Results for the year ended on 31-MAR-2008 as follows: Net Sales of Rs. 130096.39 lacs for year ending on 31-MAR-2008 against Rs. 98508.07 lacs for the year ending on 31-MAR-2007. Net Profit / (Loss) of Rs. 17533.99 lacs for the year ending on 31-MAR-2008 against Rs. 7859.64 lacs for the year ending on 31-MAR-2007.21 May · Board meeting
To approve the audited financial results of the Company for the financial year ended March 31, 2008. Consider recommendation of dividend on equity capital for the financial year ended March 31, 2008.6 May · Updates
Compensation Committee of the Board, has revised by increasing the exercise period of options granted under ORCHID - ESOP 1999 and ORCHID - ESOP 2005 Schemes to 3 years from the date of vesting.2 May · Allotment of Equity Shares
Allotment Committee of the Board of Directors of the Company at their meeting held on April 26, 2008 have allotted 9,425 equity share of Rs. 10 each as per particulars given below : 1) 7,525 equity shares of Rs. 10 each (7,400 equity shares at an adjusted price of Rs. 200.44 per share and 125 equity shares at a price of Rs. 193.25 per share) to the employees under ESOP 1999 Scheme and 2) 1,900 equity shares of Rs. 10 each at a price of Rs. 193.25 per share to the employees under ESOP 2005 Scheme. The above equity shares will be locked in for a period of one year from the date of Allotment. Consequent to this allotment, the paid-up capital of the Company has increased from Rs. 658,507,760 to Rs. 658,602,010.
Apr 2008
30 Apr · Results
Company will be publishing the audited financial results for the year ended March 31, 2008 within a period of 3 months, i.e. on or before June 30, 2008.22 Apr · Business
Press release dated April 22, 2008, titled "Ranbaxy and Orchid announce strategic business alliance - To leverage respective strengths for mutually beneficial business growth". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.10 Apr · Business
Media release dated April 10, 2008, titled "Orchid announces the formation of its Japanese Subsidiary, Orchid Pharma Japan KK - To drive foray into the growing high potential Japanese generics market". A copy of the media release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Mar 2008
18 Mar · Business
Press Release dated March 18, 2008 titled " Orchid Chemicals clarifies on market fall of its shares". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Feb 2008
20 Feb · Business
Press release dated February 20, 2008, titled "Orchid receives US FDA approval for Cefuroxime Axetil ANDA ". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.14 Feb · Business
Press release dated February 14, 2008, titled "Orchid receives USFDA nod for Granisetron generic formulation First Indian company to be approved for this non-antibiotic product". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.8 Feb · Business
Press release dated February 08, 2008, titled "Orchid ropes in Dr Gopalan to head its Drug Discovery initiatives; To head Orchid Research Labs as CSO & Director". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.6 Feb · Management
Dr Bishwajit Nag, Director has resigned from the Board of Orchid Chemicals & Pharmaceuticals Limited with effect from February 04, 2008
Jan 2008
17 Jan · Business
Press release dated January 17, 2008, titled "Orchid's Q3 FY08 revenue up by 39% to Rs 333 crore; Net Profit rises by 91% to Rs. 54 crore". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.17 Jan · Results
Standalone Results for the quarter ended on 31-DEC-2007 as follows: Net Sales of Rs. 33268.9 lacs for quarter ending on 31-DEC-2007 against Rs. 23873.33 lacs for the quarter ending on 31-DEC-2006. Net Profit / (Loss) of Rs. 5411.73 lacs for the quarter ending on 31-DEC-2007 against Rs. 2832.35 lacs for the quarter ending on 31-DEC-2006.11 Jan · Business
Press release dated January 11, 2008, titled "Orchid's formulation facilities receive MCC (South Africa) nod Cephalosporin & Penicillin Injectable facilities approved". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.7 Jan · Board meeting
To take on record the un-audited financial results of the Company for the period from October 01, 2007 to December 31, 2007.
Dec 2007
31 Dec · Allotment of Equity Shares
The Allotment Committee of the Board of Directors at its meeting held on December 20, 2007 have allotted 3000 equity Shares of Rs. 10/-each to Shri R. Narayanan, Director under ORCHID-ESOP99 Scheme
Nov 2007
16 Nov · Business
Press release dated November 16, 2007, titled "Orchid receives US FDA approval for Cefpodoxime Proxetil ANDA". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Oct 2007
18 Oct · Business
Press release dated October 18, 2007, titled "Orchid's Q2 FY08 revenue higher by 20% at Rs 295 crore ; Net profit jumps 115% to Rs 63 crore". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.18 Oct · Allotment of shares
The Allotment Committee of the Board has allotted shares as follows: (1) 5650 shares at an adjusted price of Rs.200.44 per share to employees under ORCHID ESOP 1999 Scheme on July 17, 2007. (2) 6000 shares at an adjusted price of Rs.200.44 per share to employees under ORCHID ESOP 1999 Scheme on October 18, 200718 Oct · Results
Standalone Results for the quarter ended on 30-SEP-2007 as follows: Net Sales of Rs. 29512.98 lacs for quarter ending on 30-SEP-2007 against Rs. 24573.13 lacs for the quarter ending on 30-SEP-2006. Net Profit / (Loss) of Rs. 6327.26 lacs for the quarter ending on 30-SEP-2007 against Rs. 2945.08 lacs for the quarter ending on 30-SEP-2006.8 Oct · Board meeting
To take on record the Un-audited financial results for the period from July 01, 2007 to September 30, 2007.
Sep 2007
13 Sep · Meeting
Proceedings of the Annual General Meeting of the Company held on July 19, 2007. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jul 2007
30 Jul · Business
Media release dated July 28, 2007, titled "Orchid's Managing Director honoured with Doctorate by leading university". A copy of the media release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.20 Jul · Business
Press release dated July 20, 2007, titled "Orchid receives US FDA approval for its Cefdinir ANDAs". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.19 Jul · Business
Press release dated July 19, 2007, titled "Orchid Q1 FY 2007-08 net profit surges by 252% to Rs 51 crore". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.19 Jul · Results
Consolidated Results for the quarter ended on 30-JUN-2007 as follows: Net Sales of Rs. 25176.97 lacs for quarter ending on 30-JUN-2007 against Rs. 21264.9 lacs for the quarter ending on 30-JUN-2006. Net Profit / (Loss) of Rs. 4858.94 lacs for the quarter ending on 30-JUN-2007 against Rs. 1083.24 lacs for the quarter ending on 30-JUN-2006.19 Jul · Results
Standalone Results for the quarter ended on 30-JUN-2007 as follows: Net Sales of Rs. 23819.64 lacs for quarter ending on 30-JUN-2007 against Rs. 20170.98 lacs for the quarter ending on 30-JUN-2006. Net Profit / (Loss) of Rs. 5129.8 lacs for the quarter ending on 30-JUN-2007 against Rs. 1459.09 lacs for the quarter ending on 30-JUN-2006.11 Jul · Board meeting
Meeting on 19 Jul 2007: “Unaudited financial results for quarter ended June 30, 2007”9 Jul · Meeting
Notice of the Annual General Meeting of the members of the Company to be held on July 19, 2007. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jun 2007
21 Jun · Business
"Orchid has received approval from the US FDA for its ANDA (Abbreviated New Drug Application) for CEfepime injection. The product is available in three dosage strength 500 mg/vial, 1 gram/vial, and 2 grams/vial". A copy of the press release dated June 21, 2007, titled "Orchid receives US FDA approval for its Cefepime ANDA" shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.15 Jun · Meeting
Annual General Meeting of the Company has been proposed to be held on July 19, 2007. The dates of closure of Register of Members for the purpose of Annual General Meeting and for payment of dividend has been fixed by the Board from July 15, 2007 to July 19, 2007 (both days inclusive).15 Jun · Business
Press release dated June 15, 2007, titled "Orchid forays into the non-antibiotic generic formulations segment". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
May 2007
18 May · Strike
" a section of the workmen at Orchid's Alathur - API Plant are on an illegal strike, demanding increase in wages & benefits. The Management is working very closely with the State Government Labour Department to resolve the issues.The operations are being carried on with the majority of personnel attending the duties.5 May · Allotment of shares
May 04, 2007 that "The Allotment Committee of the Board of Directors of Orchid Chemicals & Pharmaceuticals Limited at their meeting held on May 3, 2007 have allotted 6,085 equity shares of Rs. 10 each (375 equity shares at an adjusted price of Rs. 162.24 per share, 210 equity shares at an adjusted price of Rs. 168 per share and 5,500 equity shares at an adjusted price of Rs. 200.44 per share) to the emplyoees under ESOP 1999 Scheme. The equity shares allotted will be locked in for a period of one year from the date of Allotment. Consequent to this allotment, the paid-up capital of the Company has increased from Rs. 658,162,910 to Rs. 658,223,760."3 May · Business
Press release dated May 03, 2007, titled "Orchid's turnover rises to Rs.934 crore during FY 2006-07- Net profit increases to Rs 97 crore". The copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.3 May · Dividend
Board of Directors of the Company at its meeting held on May 03, 2007 have recommended a dividend of 30% (Rs.3/- per share) on the equity share of Rs.10/- each.
Apr 2007
30 Apr · Business
"Orchid's wholly-owned Drug Discovery subsidiary in Chennai, Orchid Research Laboratories Ltd (ORLL) has been conferred the Frost & Sullivan Award for Partner of Choice in Contract Research - Collaborative Drug Discovery". A copy of the press release issued by the Company dated April 30, 2007, titled "Orchid's drug discovery subsidiary (Orchid Research Labs) awarded Partner of Choice award by Frost & Sullivan" shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.25 Apr · Board meeting
(1) Adopt the audited financial results of Orchid for the financial year ended March 31, 2007. (2) Consider recommendation of dividend on equity capital for the financial year ended March 31, 2007.3 Apr · Business
"Orchid has received the approval from the Canadian TPD (Therapeutic Product Directorate) for 2 of its ANDS (Abbreviated New Drug Submission) applications. These approvals correspond to two generic formulations, Cefoxitin and Ceftriaxone". Further the Company has submitted a copy of press release dated April 03, 2007, titled "Orchid to foray into the Canadian generic formulations market". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Mar 2007
6 Mar · Miscellaneous
That the Board of Director have forfeited the 10% of the share price amount paid, aggregating to Rs. 805.54 lakhs, by Mrs. R. Vijayalakshmi (Promoter) and Dr. M R Girinath (Promoter Group) on account of the non-conversion of the 35,60,000 share warrants into equity within the stipulated period of 18 months from the date of allotment of warrants (i.e. on or before February 01, 2007)2 Mar · Foreign Currency Convertible Bonds
"The Allotment Committee of the Board of Directors of Orchid Chemicals & Pharmaceuticals Limited held on February 27, 2007 has allotted Zero Coupon Foreign Currency Convertible Bonds due 2012 (FCCBs), aggregating US$ 175 million (US $ one hundred and seventy five million only). The above bonds are listed on the Singapore Stock Exchange from February 28, 2007". The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.2 Mar · Allotment of Warrants
The Allotment committee of the Board of Directors of Orchid Chemicals & Pharmaceuticals Limited on March 01, 2007, have allotted 50,00,000 (fifty lakh only) Warrants convertible into equity to the following persons. Each warrant is convertible into one equity share of Rs.10 each within eighteen months from the date of Allotment, at a price of Rs.202.58 (Rupees two hundred and two and paise fifty eight only). 1) Name of the Allottee: Promoter - Ms.R.Divya (D/o Shri K Raghavendra Rao, Managing Director & Promoter of Orchid Chemicals & Pharmaceuticals Limited); No. of Warrants - 24,82,500. 2) Name of the Allottee: Promoter - Ms.R.Sowmya (D/o Shri K Raghavendra Rao, Managing Director & Promoter of Orchid Chemicals & Pharmaceuticals Limited); No. of Warrants - 24,82,500. 3) Name of the Allottee: Promoter Group - Dr.M.R.Girinath; No. of Warrants - 35,000. Total No. of Warrants - 50,00,000
Feb 2007
26 Feb · Business
Press release dated February 25, 2007, titled "Orchid's Zero coupon FCCB issue to retire foreign currency debt and support other business purposes". The copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.23 Feb · Issue of Warrants
Shareholders of the Company have approved the issue of 50,00,000 Warrants on a preferential basis to the promoters / Promoter Group(s) / relatives of the Promoters each convertible into one equity share of the Company of nominal value of Rs. 10/- each at a premium of Rs. 192.58, at an Extraordinary General Meeting (EGM) held on February 14, 2007. Further the Company has submitted a copy of the resolution passed by the Shareholders at the EGM the details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.16 Feb · Meeting
Shareholders of the Company have approved the issue of 50,00,000 Warrants on a preferential basis to the promoters / Promoter Group(s) / relatives of the Promoters each convertible into one equity share of the Company of nominal value of Rs. 10/- each at a premium of Rs. 192.58, at an Extraordinary General Meeting (EGM) held on February 14, 2007. Further Company has submitted a copy of resolution passed by the Shareholders at the EGM. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.13 Feb · Foreign Currency Convertible Bonds
Pursuant to the approval received from the shareholders for raising funds in the overseas markets, Orchid Chemicals & Pharmaceuticals Ltd., has placed a zero coupon Foreign Currency Convertible Bond (FCCB) offering of USD 175 million with a greenshoe option of USD 25 million, aggregating to USD 200 million. The bonds are convertible at an initial conversion price of Rs 348.34 which represents a premium of 30% over Monday's (February 12, 2007) closing price of the company's scrip on the NSE (Rs 267.95). This works out to a conversion price of Rs 348.34. The bonds have a maturity period of 5 years. Merrill Lynch International have acted as the sole bookrunner to the issue. This offering is subject to fulfillment of various conditions including approvals by the Singapore Stock Exchange and Bombay Stock Exchange (BSE), National Stock Exchange (NSE) and Madras Stock Exchange (MSE). This offering is not an offer of securities for sale in the United States. The securities offered have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or any applicable state securities laws, and may not be offered or sold within the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state securities laws. This offering shall not constitute an offer to sell or a solicitation of an offer to buy securities nor shall there be any sale of any securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.